Jessie Au, PharmD, PhD
Dr. Au received her Pharm.D. and Ph.D. degrees from University of California, San Francisco and postdoctoral training at Roswell Park Cancer Institute. Dr. Au is recognized for her accomplishments in pharmaceutical and cancer research. Her breadth of interests and training in both clinical and basic sciences have allowed Dr. Au to excel in translating her laboratory discoveries in cellular and molecular pharmacology of anticancer drugs into clinical applications. Dr. Au is among the top 5% recipients of NIH funding over 25 years.
Dr. Au is a Fellow of the American Association for the Advancement of Science and a Fellow of the American Association of Pharmaceutical Scientists. Dr. Au is recipient of several awards from the Ohio State University (Distinguished Scholar Award, Davis Chair in Cancer Research, Distinguished University Professorship), the National Cancer Institute (Research Career Development Award, MERIT Award), and a Research Award from American Association of Pharmaceutical scientists. Dr. Au’s pioneering work in systems translational research led to her nomination and selection as a semi-finalist for the inaugural NIH Directors Pioneer Award.
Dr. Au was Director of Translational Research and Deputy Director of the Ohio State University Comprehensive Cancer Center. Dr. Au has served on numerous NIH Committees and scientific advisory boards of academic centers and pharmaceutical companies, several editorial Boards, and the FDA Pharmaceutical Sciences Advisory Committee. Dr. Au recently moved from Ohio State University to become the Chief Scientific Officer of Optimum Therapeutics where she continues her NIH-funded research focusing on bringing laboratory discoveries to clinical evaluation. For more information click here.